Skip to content
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 24, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has recommended the
Toggle Summary Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three


There are currently no events to display.


There are no items to display.